AXNX - Axonics Modulation Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.41
-0.68 (-1.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close36.09
Open34.84
Bid0.00 x 1300
Ask0.00 x 1400
Day's Range34.23 - 36.10
52 Week Range18.08 - 43.37
Volume453,291
Avg. Volume670,719
Market Cap1.202B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Insiders Roundup: Uber, AutoNation
    GuruFocus.com

    Insiders Roundup: Uber, AutoNation

    Largest insider trades of the week Continue reading...

  • Market Sentiment Around Loss-Making Axonics Modulation Technologies, Inc. (NASDAQ:AXNX)
    Simply Wall St.

    Market Sentiment Around Loss-Making Axonics Modulation Technologies, Inc. (NASDAQ:AXNX)

    Axonics Modulation Technologies, Inc.'s (NASDAQ:AXNX): Axonics Modulation Technologies, Inc., a medical technology...

  • Is Axonics Modulation Technologies, Inc. (AXNX) A Good Stock To Buy?
    Insider Monkey

    Is Axonics Modulation Technologies, Inc. (AXNX) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • Axonics Modulation Technologies, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    Axonics Modulation Technologies, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

    It's been a pretty great week for Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) shareholders, with its shares...

  • Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

    Axonics (AXNX) delivered earnings and revenue surprises of -21.92% and -9.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Bullish on Axonics' Prospects
    GuruFocus.com

    Analysts Bullish on Axonics' Prospects

    Rated a buy with target set 40% above current stock price Continue reading...

  • Have Insiders Been Selling Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Shares?
    Simply Wall St.

    Have Insiders Been Selling Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • 3 Buy-Rated Stocks That Barclays Says Look Cheap
    TipRanks

    3 Buy-Rated Stocks That Barclays Says Look Cheap

    The storied City of London was once the center of global finance, and while that title has passed to Wall Street, London remains the headquarters for some of the world’s largest banks and investment firms. Barclays, first established in the goldsmith business in 1690, is one of these. Today is a major conglomerate and a powerful name in the global banking industry.Barclays is ranked 12 out of 50 in the TipRanks database of major investment research firms. At last count, the bank supported a cadre of 256 financial analysts and investment experts, whose 12,000 combined recommendations have a 58% success rate and a 6.1% average return.So, let’s take a look at three Buy stocks which Barclays analysts have recently given a thumbs up:Sundial Growers (SNDL)Canada’s recently legalized cannabis industry has already brought a series of mid- to large-cap producers to investors’ attention, but the new market is also a fertile ground for start-up players. Sundial is a new company, based in Alberta, where it produces a several lines of high-quality lines of cannabis for the recreational and wellness markets.The company plays its ‘Alberta heartland’ origin for an asset, boasting that it combines ‘tried-and-true heartland farming with innovative horticultural techniques’ in its production operations. Where many of Canada’s cannabis companies aim for mass or large-scale production in the grow houses, Sundial focuses on producing a consistent, pure strain that customers will find reliable.Sundial’s focus on product quality over rapid growth has put it in on a faster path toward profitability, in an industry where most of Canada’s cannabis companies operate in the red. Sundial’s overhead is among the lowest of its peers, with operating expenses rated at 50% of total sales compared to an sector average of 171%.Barclays' Lauren Lieberman is bullish on Sundial in the volatile Canadian cannabis sector. She says, “The company can set itself apart from peers given a focus on profitable growth. Sundial is already nearly profitable in its Canadian home market, and its acquisition of Bridge Farm should enable the company to ultimately become a low-cost mass-scale producer of CBD products.” Her price target, $7, represents a 107% upside potential for the stock. (To watch Lieberman's track record, click here)Overall, Sundial is considered a Moderate Buy from the analyst consensus, based on 2 Buys and 2 Holds. The stock only IPOd in July of this year, and was considered overvalued at that time; shares have fallen from an August peak of $13 to the current $3.25. The average price target now, however, is $9.75, suggesting room for a 200% upside. (See Sundial Growers stock analysis on TipRanks)Ping Identity Holding (PING)Shifting our focus from cannabis to technology, we find Ping. Ping inhabits the security and infrastructure segments of the software sector. The Denver-based company held its IPO just last month, and so does not have a public record of earnings reports to lean on, but its wide variety of products give it a strong position in identity security.Ping’s products – whether cloud or on-site software based – are designed for a combination of system security and an easy user interface. They are meant to connect users and devices to outside applications through an intelligent platform that treats security in a proactive fashion.This strong niche position in the security segment hasn’t prevented PING shares from declining sharply since the September IPO. Share price has lost over 15% since then, although the company’s market cap remains above $1.3 billion.Barclays’ 5-star analyst Saket Kalia sees the fall in share value as a buying opportunity. Finding room for a 23% upside to the stock, he writes: “We initiate on Ping Identity with an Overweight rating and $21 price target given: 1) the $7.5B IAM market is seeing share shift away from tech conglomerates toward security specialists like Ping; 2) Ping casts a wide net with its broad portfolio and flexible deployment, which resonates with enterprises; 3) …we think Ping offers exposure to the important identity and access management (IAM) market at a reasonable valuation and is a good risk-reward at these levels…” (To watch Kalia's track record, click here)Kalia is right in-line with the consensus on Ping. Since the IPO, the company has received 10 initiated ratings, all Buys, making the consensus rating of Strong Buy unanimous. Shares are priced at $16.70, and the average target of $21.75 suggests a 29% upside potential. (See PING stock analysis on TipRanks)Axonics Modulations Technologie (AXNX)Switching to the biotech industry, Axonics is another company that has recently gone public. The company inhabits the sacral neuromodulation space, developing non-drug therapies for forms of urinary or fecal incontinence related to weakness in the pelvic floor. The therapy involves implantation of an electrical stimulator for the sacral nerve, the main nerve route from the lower back to the pelvic region.As populations age, sacral neuromodulation will likely become more popular. It treats a set of common conditions that are related to aging, and has proven effective on symptoms that patients are eager to treat. Axonics products enter this biotech treatment space in direct competition with existing systems and patents developed by competitor Medtronic.Medtronic, however, has not been able to capitalize on its lead in this market. That company introduced its first approved product back in 1997, and has since launched only one upgrade, back in 2006. This leaves an open space for an aggressive competitor, and Axonics received approval this past September for its own fecal incontinence treatment.Like the stocks above, AXNX shares have slipped in recent weeks but Barclays sees that as a chance to ‘buy the dip.’ Also like the stocks above, Barclays analyst Kristen Stewart has just initiated coverage of this stock, noting several important points: “We see this as a sales execution story. With a superior product, we believe Axonics can gain share and expand the market—our 40-physician survey supports this view… We believe the pullback has created an opportunity for investors and see the likely FDA approval for urinary indications as a positive catalyst.”She uses that to support her Buy rating and $43 price target. She also adds, “We believe AXNS has the opportunity to penetrate the $650 million sacral neuromodulation market following FDA approval of its r-SNM system, which we anticipate to occur in 2H19.” Her target implies an impressive upside for the stock, of 77%. (To watch Stewart's track record, click here)Overall, the consensus on AXNX is a Strong Buy, based on 3 Buy ratings set in the last month. The stock has an average price target of $46.50, suggesting an upside of 91% from the current share price of $24.27. (See Axonics stock analysis on TipRanks)

  • Hedge Funds Have Never Been This Bullish On Axonics Modulation Technologies, Inc. (AXNX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Axonics Modulation Technologies, Inc. (AXNX)

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

  • Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study
    Zacks

    Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study

    Axonics (AXNX) expects to improve performance on the positive outcome of the study.

  • Is There An Opportunity With Axonics Modulation Technologies, Inc.'s (NASDAQ:AXNX) 40% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With Axonics Modulation Technologies, Inc.'s (NASDAQ:AXNX) 40% Undervaluation?

    Does the September share price for Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) reflect what it's really worth...

  • GuruFocus.com

    Axonics Modulation Technologies Inc (AXNX) CEO Raymond W Cohen Bought $106,435 of Shares

    CEO of Axonics Modulation Technologies Inc (30-Year Financial, Insider Trades) Raymond W Cohen (insider trades) bought 3,500 shares of AXNX on 08/06/2019 at an average price of $30.41 a share. Continue reading...

  • Is Axonics Modulation Technologies (NASDAQ:AXNX) Using Debt In A Risky Way?
    Simply Wall St.

    Is Axonics Modulation Technologies (NASDAQ:AXNX) Using Debt In A Risky Way?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Hedge Funds Have Never Been More Bullish On Axonics Modulation Technologies, Inc. (AXNX)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Axonics Modulation Technologies, Inc. (AXNX)

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]

  • Why Axonics Modulation Technologies Stock Soared 63% in May
    Motley Fool

    Why Axonics Modulation Technologies Stock Soared 63% in May

    This medical device stock has been on a tear since the company's Halloween 2018 IPO.

  • Associated Press

    Axonics: 1Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 47 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...

  • Ciena (CIEN) to Report Q1 Earnings: A Beat in the Offing?
    Zacks

    Ciena (CIEN) to Report Q1 Earnings: A Beat in the Offing?

    Ciena's (CIEN) fiscal first-quarter earnings are likely to gain from year-over-year higher revenues resulting from its long-term investments to meet customer needs.